| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
|
N Engl J Med
|
2000
|
29.25
|
|
2
|
Biochemistry and molecular cell biology of diabetic complications.
|
Nature
|
2001
|
25.43
|
|
3
|
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
|
N Engl J Med
|
1992
|
18.74
|
|
4
|
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.
|
Lancet
|
2003
|
9.98
|
|
5
|
Oxidative stress and diabetic vascular complications.
|
Diabetes Care
|
1996
|
5.97
|
|
6
|
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.
|
Lancet
|
1993
|
5.46
|
|
7
|
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
|
Lancet
|
2003
|
4.99
|
|
8
|
Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3.
|
J Am Coll Cardiol
|
2000
|
3.67
|
|
9
|
Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction-I.
|
Arch Intern Med
|
1998
|
2.80
|
|
10
|
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
|
Circulation
|
2004
|
2.73
|
|
11
|
Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension.
|
Hypertension
|
2000
|
2.55
|
|
12
|
Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction.
|
Circulation
|
1994
|
2.53
|
|
13
|
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
|
Circulation
|
2002
|
2.41
|
|
14
|
Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure.
|
Congest Heart Fail
|
2002
|
2.18
|
|
15
|
Treatment and outcome of myocardial infarction in hospitals with and without invasive capability. Investigators in the National Registry of Myocardial Infarction.
|
J Am Coll Cardiol
|
2000
|
2.07
|
|
16
|
Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy.
|
Circulation
|
2001
|
2.07
|
|
17
|
Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes.
|
Circ Res
|
2001
|
1.97
|
|
18
|
Angiotensin II-forming pathways in normal and failing human hearts.
|
Circ Res
|
1990
|
1.97
|
|
19
|
Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure.
|
Circulation
|
1998
|
1.90
|
|
20
|
Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease.
|
Circulation
|
2000
|
1.82
|
|
21
|
Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart.
|
Circ Res
|
2002
|
1.70
|
|
22
|
Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol.
|
Diabetes
|
2002
|
1.67
|
|
23
|
Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction.
|
Circulation
|
2002
|
1.57
|
|
24
|
Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death.
|
Diabetes
|
2001
|
1.53
|
|
25
|
Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II- dependent.
|
Lab Invest
|
2000
|
1.51
|
|
26
|
Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction.
|
Diabetes Care
|
2001
|
1.37
|
|
27
|
Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients.
|
Circulation
|
2001
|
1.24
|
|
28
|
Management and outcomes for black patients with acute myocardial infarction in the reperfusion era. National Registry of Myocardial Infarction 2 Investigators.
|
Am J Cardiol
|
1998
|
1.11
|
|
29
|
Enhanced expression and activity of xanthine oxidoreductase in the failing heart.
|
J Mol Cell Cardiol
|
2000
|
1.02
|
|
30
|
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
|
Circulation
|
2004
|
1.00
|
|
31
|
The oxidative stress hypothesis of congestive heart failure: radical thoughts.
|
Chest
|
2001
|
0.94
|
|
32
|
Confirmation of superoxide generation via xanthine oxidase in streptozotocin-induced diabetic mice.
|
Free Radic Res
|
2003
|
0.93
|
|
33
|
Accelerating impact of diabetes mellitus on mortality in the years following an acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation.
|
Eur Heart J
|
1999
|
0.93
|
|
34
|
Heart failure, redox alterations, and endothelial dysfunction.
|
Hypertension
|
2001
|
0.91
|
|
35
|
Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress.
|
Heart
|
2003
|
0.89
|
|
36
|
Increased formation of F(2)-isoprostanes in patients with severe heart failure.
|
Heart
|
2000
|
0.88
|
|
37
|
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
|
Circulation
|
2002
|
0.81
|
|
38
|
Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure.
|
Am Heart J
|
2003
|
0.77
|
|
39
|
Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology.
|
Oxid Med Cell Longev
|
2016
|
0.75
|